The US Food and Drug Administration’s human drug, biologic and medical device user fee programs require reauthorization every five years. Legislation to accomplish that task is often referred to as a “Christmas tree” because many other bills, or parts of bills, are tacked onto the must-pass measure, like ornaments placed on an evergreen during the holiday season.
The current prescription drug, generic drug and biosimilar user fee programs expire on 30 September, and lawmakers are actively jockeying...
